Skip to main content

Sanger Institute, Definiens, RheoGene, Xenogen, Flyion, MDS Sciex

Premium

Sanger Institute to Use Definiens Image-Analysis Software

Definiens said last week that the Wellcome Trust Sanger Institute has licensed its Cellenger image-analysis software.

Researchers at the Sanger Institute will use the software two support two projects, the Atlas of Protein Expression and the Embryo Gene Expression program, Definiens said.

Both of these projects are developing terabyte-scale databases of expression data using high-throughput immunohistochemistry. The researchers are using Cellenger to improve the throughput, analysis, and annotation of images generated by these programs.

Financial terms of the agreement were not disclosed.


RheoGene Licenses Technology to Xenogen Biosciences to Develop Transgenic Mice

RheoGene has licensed its RheoSwitch System technology to Xenogen Biosciences to develop transgenic mice as animal research models, the Norristown, Penn.-based company said last week.

"The objective of this research collaboration is to establish and validate RheoSwitch technology within the transgenic mouse setting through the creation of genetically modified animals," said Thomas Tillett, RheoGene's president and CEO.

The companies will also collaborate on several projects aimed at controlling delivery and regulating expression of RNAi in order to address the problems of timing and localizing active RNAi products to various target sites in vivo.


Flyion Installs Patch-Clamp Robot at Finnish Pharma Orion

German biotech Flyion said last week that it has successfully installed a Flyscreen 8500 patch-clamp robot at Orion Pharma in Finland.

Orion will use the technology in its ion channel drug screening programs, Flyion said.

Financial terms of the agreement were not disclosed.


MDS Sciex's Revenues Decline 5 Percent in Q3; Parent MDS Writes Off $8M in Protana License Fees

MDS last week reported a 5-percent drop in third-quarter revenue from its analytical instruments business, MDS Sciex.

Analytical instruments, which are part of MDS' life sciences businesses, recorded $74 million for the quarter, down from $78 million for the same quarter a year ago. This drop was due mainly to currency effects and weaker sales of ICP/MS mass spec-based products.

The company said it achieved "strong performance" from its QTRAP mass spectrometers for biomarker and small molecule analysis. Also, its 4,800 MALDI TOF/TOF mass spectrometer "has been well received by our proteomics and biomarker customers," according to the company.

MDS Sciex recently launched a new cellular analysis instrument, the CellKey, out of its life sciences division.

In addition, MDS said it wrote off $8 million of $10 million in license fees this quarter that the company paid for proteomics technology from Protana, formerly MDS Proteomics. "Based on our realigned operational plan for MDS Pharma Services, we have decided to use a different technology, and we do not expect to recover our investment in this license," according to a company statement.

 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.